[go: up one dir, main page]

ME00804B - Anti-alpha v beta 6 antitela - Google Patents

Anti-alpha v beta 6 antitela

Info

Publication number
ME00804B
ME00804B MEP-2009-200A MEP20009A ME00804B ME 00804 B ME00804 B ME 00804B ME P20009 A MEP20009 A ME P20009A ME 00804 B ME00804 B ME 00804B
Authority
ME
Montenegro
Prior art keywords
antibody
seq
αvβ6
light chain
sequence
Prior art date
Application number
MEP-2009-200A
Other languages
English (en)
French (fr)
Inventor
Michael Graupe
Paul Weinreb
Kenneth Simon
Dean Sheppard
Diane Leone
Original Assignee
Biogen Idec Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29586753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00804(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Univ California filed Critical Biogen Idec Inc
Publication of ME00804B publication Critical patent/ME00804B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)

Abstract

Monoklonska antitela koja se specifično vezuju za  α v β 6 .  Uključeni su i postupci  korišćenja ovih antitela za tretiranje sisara koji imaju oboljenja u kojima posreduje  α v β 6 , ili su  pod rizikom da ih imaju, ili za dijagnostikovanje oboljenja u kojima posreduje  α v β 6 .

Claims (59)

1. Monoklonsko antitelo koje (a) se specifično vezuje za αvβ6 (b) inhibira vezivanje αvβ6 za peptid vezan za latenciju (LAP) sa vrednošću IC50 nižom od one 10D5.
2. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.1A8 (ATCC pristupni broj PTA-3647).
3. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.309 (ATCC pristupni broj PTA-3649).
4. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.806 (ATCC pristupni broj PTA-3645).
5. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2B l (ATCC pristupni broj PTA-3646).
6. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.l G l O (ATCC pristupni broj PTA-3898).
7. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.705 (ATCC pristupni broj PTA-3899).
8. Antitelo prema zahtevu l , gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 7.1CS (ATCC pristupni broj PTA-3900).
9. Antitelo prema zahtevu l, gde je vezivanje između antitela i αvβ6 zavisno od dvovalentnih katjona.
10. Antitelo prema zahtevu l , gde je dvovalentni katjon Ca2+, Mg2+ ili Mn2+
11. Antitelo prema zahtevu l , gde je vezivanje između antitela i αvβ6 nezavisno od dvovalentnih katjona.
12. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: l , 4 i 7, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: l O, 13 i 15, respektivno.
13. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 3, 5 i 8, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 11, 14 i 17, respektivno.
14. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 3, 6 i 9, respektivno, i čiji se CDR ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 12, 14 i 18, respektivno.
15. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 2, 46 i 47, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 48, 13 i 16, respektivno.
16. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 49, 51, i 53, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 55, 57 i 59, respektivno.
17. Antitelo na αvβ6 čiji se regioni koji određuju komplementarnost teških lanaca (CDR) l , 2 i 3 sastoje suštinski od sekvenci SEQ ID NOs: 50, 52, i 54, respektivno, i čiji se CDR-ovi lakih lanaca po izboru suštinski sastoje od sekvenci SEQ ID NOs: 56, 58 i 60, respektivno.
18. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži bilo koju od SEQ ID NOs: 19-36 i 61-62.
19. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 19, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 37.
20. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID N0:20 ili 21 , a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 38.
21. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID N0:22, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 43.
22. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 23, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 44.
23. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 24, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 45.
24. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 25 ili 26, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 42.
25. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 27, 28, ili 29, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 39.
26. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 34 ili 35, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 40.
27. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 36, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 41.
28. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 61, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 63.
29. Antitelo na αvβ6 koje kao sekvencu varijabilnog domena teškog lanca sadrži SEQ ID NO: 62, a kao sekvencu varijabilnog domena lakog lanca SEQ ID NO: 64.
30. Monoklonsko antitelo koje se specifično vezuje za αvβ6, ali ne inhibira vezivanje αvβ6 za peptid vezan za latenciju (LAP).
31. Antitelo prema zahtevu 30, gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2A l (ATCC pristupni broj PTA-3896).
32. Antitelo prema zahtevu 30, gde se antitelo sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2E5 (ATCC pristupni broj PTA-3897).
33. Kompozicija za sprečavanje ili lečenje oboljenja u kojem posreduje αvβ6 kod sisara, koja sadrži antitelo iz bilo kog od zahteva 1-32, i farmaceutski prihvatljiv nosač.
34. Kompozicija prema zahtevu 33, gde je antitelo konjugovano sa citotoksičkim agensom.
35. Kompozicija prema zahtevu 33, gde je antitelo zavisno od katjona.
36. Postupak za tretiranje subjekta koji ima ili je pod rizikom da ima oboljenje u kojem posreduje αvβ6, koji se sastoji od davanja subjektu kompozicije iz zahteva 32, čime se ublažava oboljenje ili odlaže njegov početak.
37. Postupak prema zahtevu 36, gde je subjekt čovek.
38. Postupak prema zahtevu 36, gde je oboljenje fibroza.
39. Postupak prema zahtevu 38, gde je fibroza skleroderma, stvaranje ožiljaka, fibroza jetre, fibroza bubrega ili fibroza pluća.
40. Postupak prema zahtevu 36, gde je oboljenje psorijaza.
41. Postupak prema zahtevu 36, gde je oboljenje kancer.
42. Postupak prema zahtevu 41, gde je kancer epitelni kancer.
43. Postupak prema zahtevu 41, gde je kancer oralan, kancer kože, cerviksa, jajnika, farinksa, larinksa, ezofagusa, pluća, dojke, bubrega ili kolorektalni kancer.
44. Postupak prema zahtevu 36, gde je oboljenje Alport-ov sindrom.
45. Postupak detektovanja αvβ6 u uzorku tkiva sisara, koji se sastoji od dovođenja u kontakt uzorka tkiva sa antitelom iz zahteva l ili 30.
46. Postupak prema zahtevu 45, gde je antitelo odabrano iz grupe koju čine 6.2Al (ATCC pristupni broj PTA 3896) i 6.2E5 (ATCC pristupni broj PTA 3897).
47. Ćelija hibridoma 6.1A8 (ATCC pristupni broj PTA-3647).
48. Ćelija hibridoma 6.2B10 (ATCC pristupni broj PTA-3648).
49. Ćelija hibridoma 6.3G9 (ATCC pristupni broj PTA-3649).
50. Ćelija hibridoma 6.8G6 (ATCC pristupni broj PTA-3645).
51. Ćelija hibridoma 6.2Bl (ATCC pristupni broj PTA-3646).
52. Ćelija hibridoma 6.2Al (ATCC pristupni broj PTA-3896).
53. Ćelija hibridoma 6.2E5 (ATCC pristupni broj PTA-3897).
54. Ćelija hibridoma 7.1G lO (ATCC pristupni broj PTA-3898).
55. Ćelija hibridoma 7.7G5 (ATCC pristupni broj PTA-3899).
56. Ćelija hibridoma 7.1C5 (ATCC pristupni broj PTA-3900).
57. Izolovana nukleinska kiselina koja sadrži kodirajuću sekvencu za bilo koju od SEQ ID NOs: 19-45 i 61-64.
58. Izolovan polipeptid koji sadrži bilo koju aminokiselinsku sekvencu od SEQ ID NOs: 19-45 i 61-64.
59. Monoklonsko antitelo koje se sastoji od istih polipeptidnih sekvenci teškog i lakog lanca kao antitelo koje je proizveo hibridom 6.2B 10 (ATCC pristupni broj PTA-3648).
MEP-2009-200A 2002-03-13 2003-03-13 Anti-alpha v beta 6 antitela ME00804B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36499102P 2002-03-13 2002-03-13
US42628602P 2002-11-13 2002-11-13
PCT/US2003/008048 WO2003100033A2 (en) 2002-03-13 2003-03-13 ANTI-αvβ6 ANTIBODIES

Publications (1)

Publication Number Publication Date
ME00804B true ME00804B (me) 2012-03-20

Family

ID=29586753

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-200A ME00804B (me) 2002-03-13 2003-03-13 Anti-alpha v beta 6 antitela

Country Status (23)

Country Link
US (4) US7465449B2 (me)
EP (4) EP2336185A1 (me)
JP (6) JP4473117B2 (me)
KR (1) KR101098109B1 (me)
CN (4) CN1646160A (me)
AR (1) AR038970A1 (me)
AU (1) AU2003261071C1 (me)
BR (1) BRPI0308585B8 (me)
CA (1) CA2478833C (me)
CL (8) CL2010000787A1 (me)
EA (1) EA011853B1 (me)
ES (1) ES2389037T3 (me)
HK (1) HK1213007A1 (me)
IL (4) IL164021A0 (me)
IS (1) IS7443A (me)
ME (1) ME00804B (me)
MX (1) MXPA04008870A (me)
MY (2) MY154009A (me)
NO (1) NO334834B1 (me)
NZ (2) NZ535425A (me)
PL (1) PL216223B1 (me)
RS (1) RS52488B (me)
WO (1) WO2003100033A2 (me)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101098109B1 (ko) * 2002-03-13 2011-12-26 더 리전츠 오브 더 유니버시티 오브 캘리포니아 항αｖβ6 항체
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
AU2012258386B2 (en) * 2005-07-08 2014-08-07 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP1974213A4 (en) * 2006-01-17 2009-03-25 Biosite Inc HIGHLY SENSITIVE SECRETAGOGIN ASSAYS AND ITS USE IN DIAGNOSIS AND / OR FORECASTING
JP2009542810A (ja) * 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
RU2009107277A (ru) * 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
JP2010506944A (ja) * 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
EP2164992B1 (en) * 2007-05-30 2016-05-04 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
US8163885B2 (en) 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
WO2009135953A2 (en) * 2008-05-09 2009-11-12 Ablynx Nv Amino acid sequences directed against integrins and uses thereof
CN102099491A (zh) 2008-05-15 2011-06-15 北卡罗来纳-查佩尔山大学 调节血管生成的新靶标
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101606236B1 (ko) 2009-08-19 2016-03-24 메르크 파텐트 게엠베하 Ｆｆｐｅ 물질 내의 인테그린 복합체의 검출용 항체
WO2011119524A1 (en) * 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
EA028899B1 (ru) * 2010-04-30 2018-01-31 Алексион Фармасьютикалз, Инк. АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
AR086364A1 (es) 2011-04-21 2013-12-11 Bayer Ip Gmbh Conjugados de principio activo-ligante (adc) y el uso de los mismos
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
AU2013221585B2 (en) * 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
JP6324970B2 (ja) 2012-09-27 2018-05-23 バイオケア メディカル， エルエルシー 抗ウロプラキンｉｉ抗体システムおよび方法
AU2013325443B2 (en) * 2012-10-03 2019-01-31 Livtech, Inc. Anti-hDlk-1 antibody having an anti-tumor activity in vivo
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
HRP20211317T1 (hr) 2013-08-30 2021-11-26 Immunogen, Inc. Antitijela i analize za detekciju folat receptora 1
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
CA2925057A1 (en) * 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
EP3052522B1 (en) 2013-10-03 2019-12-11 Biocare Medical, LLC Anti-sox10 antibody systems and methods
CN104721225A (zh) 2013-12-19 2015-06-24 高露洁-棕榄公司 口腔护理组合物
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
SG11201609912TA (en) 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
WO2016207089A1 (de) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
US10973923B2 (en) 2015-06-23 2021-04-13 Bayer Pharma Aktiengesellschaft Site specific homogeneous with KSP inhibitors
WO2017027685A2 (en) * 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3432934B1 (de) 2016-03-24 2022-02-23 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
US20190284259A1 (en) * 2016-07-22 2019-09-19 Georgia State University Research Foundation Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
KR102628678B1 (ko) 2016-12-21 2024-01-25 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
GB201720989D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
BR112020022961A2 (pt) 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP2022527372A (ja) * 2019-04-08 2022-06-01 バイオジェン・エムエイ・インコーポレイテッド 抗インテグリン抗体及びそれらの使用
GB201908536D0 (en) 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
US20230002510A1 (en) * 2019-11-26 2023-01-05 Children's Hospital Medical Center Cela-1 inhibition for treatment of lung disease
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
WO2022164816A1 (en) * 2021-01-26 2022-08-04 The Regents Of The University Of California Compositions and methods for treating and preventing disease associated with avb8 integrin
EP4288052A1 (en) 2021-02-03 2023-12-13 BP Asset V, Inc. Formulation of furin inhibitor for inhalation
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024263932A2 (en) 2023-06-23 2024-12-26 Mythic Therapeutics, Inc. Itgb6-binding proteins and uses thereof
WO2025064435A1 (en) 2023-09-19 2025-03-27 Imaginab, Inc. Antigen binding constructs directed to integrin αvβ6
WO2025163120A1 (en) 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
ATE244306T1 (de) 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CZ45498A3 (cs) 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
EP0909277B2 (en) * 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU6721696A (en) 1996-07-15 1998-03-06 Human Genome Sciences, Inc. Cd44-like protein
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
DK1930022T3 (da) * 1997-08-08 2011-07-25 Univ California Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin
JP2002501086A (ja) 1998-01-23 2002-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗−αｖインテグリンモノクローナル抗体および、フィブロネクチンへのαｖβ６インテグリンの付着を阻害するためのその使用
EP1140989A1 (de) 1998-12-19 2001-10-10 MERCK PATENT GmbH Inhibitoren des integrins alpha(v) beta(6)
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
DE10118550A1 (de) 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
EP3674322A1 (en) 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
KR101098109B1 (ko) * 2002-03-13 2011-12-26 더 리전츠 오브 더 유니버시티 오브 캘리포니아 항αｖβ6 항체
US20040048312A1 (en) 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
EP1667668B1 (en) 2003-10-01 2008-07-02 MERCK PATENT GmbH Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
ES2343840T3 (es) 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
JP2010506944A (ja) 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
WO2010072348A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20150086570A1 (en) 2012-03-29 2015-03-26 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
NZ535425A (en) 2008-05-30
JP5616932B2 (ja) 2014-10-29
US20120251532A1 (en) 2012-10-04
EP2287199B1 (en) 2017-08-02
NZ563951A (en) 2009-04-30
AU2003261071A1 (en) 2003-12-12
AR038970A1 (es) 2005-02-02
NO20044347L (no) 2004-12-13
EP2287199A2 (en) 2011-02-23
CL2010000786A1 (es) 2011-02-18
EA200401198A1 (ru) 2005-04-28
IL225633B (en) 2021-12-01
WO2003100033A2 (en) 2003-12-04
KR20040095281A (ko) 2004-11-12
IL225633A0 (en) 2014-03-31
CN102924598A (zh) 2013-02-13
JP2005528099A (ja) 2005-09-22
HK1074381A1 (en) 2005-11-11
MY147019A (en) 2012-10-15
EP1490110A4 (en) 2006-12-27
AU2003261071C1 (en) 2008-12-11
CL2010000787A1 (es) 2011-02-11
CL2010000789A1 (es) 2011-02-18
RS52488B (sr) 2013-02-28
ES2389037T3 (es) 2012-10-22
CL2010000790A1 (es) 2011-02-18
JP2009100763A (ja) 2009-05-14
IS7443A (is) 2004-09-09
JP2015126743A (ja) 2015-07-09
US20050255102A1 (en) 2005-11-17
JP2013014592A (ja) 2013-01-24
CA2478833A1 (en) 2003-12-04
WO2003100033A3 (en) 2004-07-15
CN104805090A (zh) 2015-07-29
EP2287198A3 (en) 2011-05-25
JP2015091807A (ja) 2015-05-14
JP4473117B2 (ja) 2010-06-02
EP1490110A2 (en) 2004-12-29
RS80704A (sr) 2006-12-15
CL2010000792A1 (es) 2011-02-18
US20090186036A1 (en) 2009-07-23
PL216223B1 (pl) 2014-03-31
CN102659946A (zh) 2012-09-12
BRPI0308585B8 (pt) 2021-05-25
MXPA04008870A (es) 2005-06-17
BR0308585A (pt) 2005-02-01
IL164021A0 (en) 2005-12-18
US20150140609A1 (en) 2015-05-21
EP1490110B1 (en) 2012-06-13
CL2010000785A1 (es) 2011-02-18
BRPI0308585B1 (pt) 2019-10-15
PL372662A1 (pl) 2005-07-25
EP2287198A2 (en) 2011-02-23
HK1213007A1 (zh) 2016-06-24
CA2478833C (en) 2015-11-10
EA011853B1 (ru) 2009-06-30
NO334834B1 (no) 2014-06-16
CL2010000791A1 (es) 2011-02-18
MY154009A (en) 2015-04-30
US7465449B2 (en) 2008-12-16
KR101098109B1 (ko) 2011-12-26
CN102924598B (zh) 2014-12-31
US8153126B2 (en) 2012-04-10
CL2010000788A1 (es) 2011-02-18
US9745376B2 (en) 2017-08-29
AU2003261071B2 (en) 2008-05-15
EP2287199A3 (en) 2011-05-25
CN1646160A (zh) 2005-07-27
EP2336185A1 (en) 2011-06-22
JP2012228269A (ja) 2012-11-22
IL164021A (en) 2013-04-30

Similar Documents

Publication Publication Date Title
ME00804B (me) Anti-alpha v beta 6 antitela
JP2005528099A5 (me)
RU2009148600A (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
ME02581B (me) Farmaceutski pripravci s otpornošću na topljivi cea
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
JP2020514310A5 (me)
JP2021106617A5 (me)
HRP20131085T1 (hr) Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
HRP20150965T1 (hr) Anti-fgr3 protutijela i metode koje ih koriste
JP2013056885A5 (me)
HRP20192347T1 (hr) Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
HRP20250474T1 (hr) Antitijela koja se vežu za egfr i cmet
HRP20171301T1 (hr) Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38
RU2011108260A (ru) Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
SI2342234T1 (en) MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL
JP2010504755A5 (me)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
JP2010523096A5 (me)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2010516708A5 (me)
PE20090368A1 (es) Anticuerpos anti-igf